Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2012
Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 71 citations in OpenAlex.
- Trial
- Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer.Radiation oncology (London, England) · 2014Trial
- The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801.Lung cancer (Amsterdam, Netherlands) · 2013Trial
- Article
- Case report: A case of radiation-induced diffuse hemorrhagic gastroduodenitis successfully treated with thalidomide.Frontiers in pharmacology · 2026Article
- Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers.Current oncology (Toronto, Ont.) · 2024Article
- Redetermination of PD-L1 expression after chemio-radiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis.Frontiers in oncology · 2024Article
- Curative immunotherapy-based strategies for non-metastatic non-small cell lung cancer.Exploration of targeted anti-tumor therapy · 2024Review
- Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview.Metabolites · 2023Review
- Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study.Frontiers in oncology · 2023Article
- Mechanism of action of paclitaxel for treating glioblastoma based on single-cell RNA sequencing data and network pharmacology.Frontiers in pharmacology · 2022Article
- Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents.Translational lung cancer research · 2021Review
- [A Literature Review on the Role of TBX5 in Expression and Progression of Lung Cancer: Current Perspectives].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020Review
- Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.Current treatment options in oncology · 2018Review
- Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?European respiratory review : an official journal of the European Respiratory Society · 2018Review
- Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer.Cancer management and research · 2018Review
- Preparation, characterization, in vitro and in vivo anti-tumor effect of thalidomide nanoparticles on lung cancer.International journal of nanomedicine · 2018Article
- Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Article
- Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Review
- Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation?Translational lung cancer research · 2016Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
purposeThe primary objective of this study was to compare the survival of patients with unresectable stage III non-small-cell lung cancer (NSCLC) treated with combined chemoradiotherapy with or without thalidomide. PATIENTS AND
methodsPatients were randomly assigned to the control arm (PC) involving two cycles of induction paclitaxel 225 mg/m(2) and carboplatin area under the curve (AUC) 6 followed by 60 Gy thoracic radiation administered concurrently with weekly paclitaxel 45 mg/m(2) and carboplatin AUC 2, or to the experimental arm (TPC), receiving the same treatment in combination with thalidomide at a starting dose of 200 mg daily. The protocol allowed an increase in thalidomide dose up to 1,000 mg daily based on patient tolerability.
resultsA total of 546 patients were eligible, including 275 in the PC arm and 271 in the TPC arm. Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm. Overall, there was higher incidence of grade 3 toxicities in patients treated with thalidomide. Several grade 3 or higher events were observed more often in the TPC arm, including thromboembolism, fatigue, depressed consciousness, dizziness, sensory neuropathy, tremor, constipation, dyspnea, hypoxia, hypokalemia, rash, and edema. Low-dose aspirin did not reduce the thromboembolic rate.
conclusionThe addition of thalidomide to chemoradiotherapy increased toxicities but did not improve survival in patients with locally advanced NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.